This post was originally published on this site The U.S. Food and Drug Administration is delaying its decision on a new drug application (NDA) seeking approval of selinexor in combination with dexamethasone for patients with multiple myeloma who failed at least three prior therapies. This means that the FDA will decide whether to approve the oral…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Breast Cancer Survivors Weigh in on Ways to Reduce the Financial Burden of the Disease
This post was originally published on this site A qualitative study has proposed nine recommendations from breast cancer survivors about how to reduce the financial burden associated with the disease, which include changes to insurance, supportive services, financial assistance, and protective policies. The findings of the study, “Patient recommendations for reducing long‐lasting economic burden after…
Prostate Cancer Foundation Partners with CURE Media to Raise Awareness
This post was originally published on this site A new Prostate Cancer Foundation (PCF) collaboration with CURE Media Group, a multimedia platform, is expected to raise awareness of prostate cancer and enhance the scope and availability of disease information. Specifically, the PCF has joined CURE Media’s Strategic Alliance Partnership (SAP) program, which works to cultivate information-sharing…
Phase 3 Trial Launched to Test TTFields-Taxol Combo on Platinum-resistant Ovarian Cancer
This post was originally published on this site Novocure has initiated a Phase 3 trial investigating its Tumor Treating Fields (TTFields) — a method that uses electric fields to disrupt cell division — in combination with Taxol (paclitaxel) as a treatment for ovarian cancer patients who are resistant to platinum-based chemotherapy. The trial — which…
FDA Application Submitted for Darzalex Combo Therapy to Treat Certain Multiple Myeloma Patients
This post was originally published on this site An application has been submitted seeking U.S. approval of Darzalex (daratumumab) in combination with standard pre-transplant therapy to treat newly diagnosed multiple myeloma patients who are eligible for a stem cell transplant. Janssen‘s supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) is for a combination of…
UK’s NICE Recommends Adcetris as Second-line Treatment for Certain CTCL Patients
This post was originally published on this site After first rejecting it due to cost-effectiveness concerns, the National Institute for Health and Care Excellence (NICE) has now recommended the use of Adcetris (brentuximab vedotin) as a second-line therapy for patients with CD30-positive cutaneous T-cell lymphomas (CTCL). This means that CTCL patients living in the U.K. may now have access to Adcetris…
Combining DNA Damage Response Inhibitors with Immunotherapy Boosts SCLC Clearance, Mouse Study Shows
This post was originally published on this site Combining anti-PD-L1 immunotherapies with agents that inhibit the DNA damage response (DDR) significantly enhances anti-tumor immunity and leads to rapid tumor disappearance in mouse models of small cell lung cancer (SCLC), a study reports. These preclinical findings suggest that adding DDR inhibitors, such as Lynparza (olaparib) or prexasertib, to immune checkpoint…
Frying Oil Reheated Often, Like in Deep Frying, Seen to Promote Breast Cancer’s Spread in Animal Study
This post was originally published on this site Frying oil that has repeatedly been reheated to high temperatures — as can take place in deep frying of foods — may cause genetic changes that trigger the growth and spread of breast cancer, a study in a mouse model of the disease reports. The study, “Thermally…
Three Keytruda Combinations Show Signs of Efficacy in Metastatic CRPC
This post was originally published on this site Combining the immune checkpoint inhibitor Keytruda (pembrolizumab) with either a PARP inhibitor, chemotherapy, or hormone therapy led to promising signs of activity in metastatic castration-resistant prostate cancer (mCRPC) patients in a Phase 1b/2 trial, Merck — Keytruda’s developer — announced. The findings were presented at the 2019…
Revlimid/Rituxan Combo Shows Promise in Follicular, Marginal Zone Lymphomas
This post was originally published on this site Patients with follicular lymphoma and marginal zone lymphoma who failed at least one prior therapy live significantly longer — more than two years — without their disease worsening when treated with a combination of Revlimid (lenalidomide) and Rituxan (rituximab), compared to Rituxan alone, a Phase 3 trial shows. The combination was also superior…
Patients with Platinum-sensitive Ovarian Cancer Live Longer on SOTIO’s Immunotherapy, Trial Shows
This post was originally published on this site Adding SOTIO’s ovarian cancer immunotherapy DCVAC/OvCa to standard second-line chemotherapy significantly extends the lives of women with advanced ovarian cancer who initially responded to their first-line chemotherapy, a Phase 2 trial shows. The combination also extended the time patients lived without signs of disease worsening compared with…
FDA Puts Partial Hold on Venetoclax’s Multiple Myeloma Trials
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on venetoclax’s multiple myeloma trials after new safety concerns were raised during a review of the BELLINI Phase 3 trial (NCT02755597). This means that all ongoing clinical trials assessing AbbVie‘s venetoclax in multiple myeloma can no…